Browsing by Author "Abdel-Rashid R.S."

Now showing 1 - 3 of 3

Adaptation of hard gelatin capsules for oral delivery of aqueous radiopharmaceuticals
(Springer, 2019) Omar S.M.; Abdel-Rashid R.S.; AlAssaly M.K.; Sakr T.M.; Faculty of Pharmacy; Ahram Canadian University; Giza; Egypt; Department of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy; Helwan University; Ain Helwan; Cairo; 11795; Egypt; Ministry of Interior; Medical Services; Cairo; Egypt; Faculty of Pharmacy; October University of Modern Sciences and Arts; Cairo; Egypt; Radioactive Isotopes and Generators; Atomic Energy Authority; Cairo; Egypt
Purpose: Oral administration of Iodine?131 (I?131) solutions causes high risk of contamination for patients and dispensers. The objective of the study was to adapt hard gelatin capsules (HGCs) for filling with radiopharmaceutical solutions without deformation. Methods: Polystyrene (PS) internally lining films with different thicknesses were used to protect HGCs. The insulated HGCs were evaluated for their physicochemical characteristics and rupturing time in different dissolution media. HGCs internally lined with PS were examined for withstand loading with different volumes and radioactivities of I?131 solutions. Radioactivity release was studied in deionized water and acidic media. Quality control of released I?131 was inspected for radiochemical purities. Results: There was a directly proportion between PS lining thickness and stability of HGCs after filling with 500�?l aqueous methylene blue solution. HGCs internally lined with PS 100�?m thickness withstand deformation for ? two months; however showed fast in-vitro rupturing time in different dissolution media. Internally lined HGCs loaded with different volumes and radioactivities of I?131 solutions resisted for one week without radioactive leakage. Yet, revealed complete release of I?131 after 20�min in dissolution media with great radiochemical purity. Conclusion: The study promises safely I?131 aqueous solution delivery via adapted HGCs. [Figure not available: see fulltext.]. � 2019, Springer Nature Switzerland AG.
Lipid nanocarriers for tamoxifen citrate/coenzyme Q10 dual delivery
(Editions de Sante, 2017) El-Leithy E.S.; Abdel-Rashid R.S.; Department of Pharmaceutics and Industrial Pharmacy; Faculty of Pharmacy; October University for Modern Sciences and Arts (MSA); Cairo; Egypt; Department of Pharmaceutics and Industrial Pharmacy; Faculty of Pharmacy; Helwan University; Ain Helwan; Cairo; 11795; Egypt
Nanotechnology based combinatorial therapy has emerged as an effective strategy for cancer treatment due to its synergistic activity, suppression of multi-drug resistance and successful delivery to target site. The objective of this work was to develop and characterize tamoxifen citrate (TC) and coenzyme Q10 (CoQ10) lipid nanocarriers for oral breast cancer chemotherapy. Stearic acid (2%w/v) and poloxamer188 (3%w/v) were selected as optimal lipid matrix and surfactant for development of solid lipid nanocarriers (SLNs). Incorporation of lecithin into lipid matrix (SLN9) significantly reduced particle size to 180 nm and increased %EE of CoQ10 (45%). Nanostructured lipid carriers containing 10% Labrafac oil showed further decrease in particle size reaching only 81 nm and increased %EE up to 94% and 56% for TC and CoQ10, respectively. Lipid nanocapsules showed more prominent effect on decreasing particle size (36 nm). Lipid nanocarriers offered controlled drug release profiles. The study showed that lipid carriers significantly improved drugs permeation through rabbit intestinal mucosa and suggested them as potential delivery systems for improving the bioavailability of TC/CoQ10 therapeutic molecules. Subsequent studies will be performed in order to elucidate the cytotoxicity and genotoxicity of selected lipid nanocarriers formulas on MCF-7 (adenocarcinoma breast cancer cells) versus normal cells (WISH cell line). � 2017 Elsevier B.V.
Tamoxifen citrate/Coenzyme Q10 as smart nanocarriers Bitherapy for Breast Cancer: Cytotoxicity, genotoxicity, and antioxidant activity
(Editions de Sante, 2019) El-Leithy E.S.; Hassan S.A.; Abdel-Rashid R.S.; Department of Pharmaceutics and Industrial Pharmacy; Faculty of Pharmacy; Helwan University; Cairo; Egypt; Faculty of Pharmacy; Department of Pharmaceutics and Industrial Pharmacy; MSA University; Cairo; Egypt; Therapeutic Chemistry Dept; National Research Center; Cairo; Egypt
Nanotechnology-based bitherapy has recently emerged as an effective strategy to overcome biomedical barriers against successful anticancer therapy. The study aimed to evaluate lipid nanocarriers loaded with tamoxifen citrate/coenzyme Q10 (TC/CoQ10) as bitherapy for selective targeting of breast cancer. Based on a previous study, four formulations of lipid nanocarriers were selected for in-vitro cell viability estimation using both MCF-7 and normal WISH cell lines. Oxidative status, cytopathological changes, and genetoxicity were also investigated. The results showed 100% mortality for tested cells without selectivity even at very low concentration for free drugs. On the other hand lipid nanocarriers revealed an increase in % cell viability for normal WISH cell line reaching 100% at 0.25 ?g/ml. The lipid nanocarrier formulated from stearic acid and lecithin showed LC 50 on MCF-7 cell line (1.6 ?g/ml) compared to (4.8 ?g/ml) on WISH cell line. The cell death pathway for unformulated bitherapy depended on necrosis rather than apoptosis. The Malondialdehyde concentration was decreased, while Glutathione level increased to near normal values in both MCF-7 and WISH cells. The results demonstrated a promising synergistic and selective action of TC/CoQ10 bitherapy on breast cancer cells when administered in lipid nanocarriers delivery system. � 2019 Elsevier B.V.